PARIS -- France's anti-doping laboratory began analyzing
Tour de France champion Floyd Landis' "B" urine sample Monday.
The tests, which were requested by the U.S. Anti-Doping Agency,
were taking place at the Chatenay-Malabry lab outside Paris -- the
same lab that revealed Landis' positive test after he won the 17th
stage of last year's Tour.
"The analyses have indeed begun. USADA and Landis are each
represented with two experts," said Pierre Bordry, the head of the
French anti-doping agency. "The analyses should last about 10
The results will be sent directly to USADA, Bordry said.
Landis, who tested positive for a high testosterone to
epitestosterone ratio, insists the tests aren't necessary because,
except for his sample following last year's 17th stage, the other
primary "A" samples were negative for banned substances.
He wanted the tests conducted at the UCLA lab, which handles
much of USADA's testing, but the machines it uses for the tests are
Landis has an arbitration hearing scheduled for May 14 in
California, at which he is expected to question the practices at
the French lab.
If doping allegations against the 31-year-old American are
upheld, he faces a two-year ban from competition. He also would be
the first rider in the 104-year history of the Tour to be stripped
of the title. He already has agreed not to compete in this year's
event while the case is pending.